SCHEMBL4160688

SCHEMBL4160688

O=C(O)Cc1ccccc1-c1c[nH]c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.53
KMT2A Q03164 5/20 0.53
ALDH1A1 P00352 4/20 0.53
MEN1 O00255 4/20 0.53
KDM4E B2RXH2 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
HPGD P15428 2/20 0.53
SLC6A2 P23975 1/20 0.50
FNTA P49354 1/20 0.50
FNTB P49356 1/20 0.50
LMNA P02545 4/20 0.48
TSHR P16473 3/20 0.48
DNMT1 P26358 3/20 0.48
TDP1 Q9NUW8 2/20 0.48
PMP22 Q01453 2/20 0.48
POLB P06746 2/20 0.48
RECQL P46063 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
ADAM17 P78536 1/20 0.48
GLA P06280 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Indole-3-Acetic Acid SCHEMBL26344 0.82 MEN1 (0.75) MAPTKMT2AALDH1A1MEN1KDM4E
SCHEMBL8732523 0.82 IMPDH2 (0.51) MAPTKMT2AALDH1A1MEN1KDM4E
Indole-3-Acetic Acid SCHEMBL7887240 0.82 MEN1 (0.75) MAPTKMT2AALDH1A1MEN1KDM4E
Indole-3-Acetic Acid SCHEMBL29350750 0.82 MEN1 (0.75) MAPTKMT2AALDH1A1MEN1KDM4E
Indole-3-Acetic Acid SCHEMBL31084632 0.80 MEN1 (0.73) MAPTKMT2AALDH1A1MEN1KDM4E
Indole-3-Acetic Acid SCHEMBL1375190 0.80 MEN1 (0.73) MAPTKMT2AALDH1A1MEN1KDM4E
Indole-3-Acetic Acid SCHEMBL29272696 0.80 MEN1 (0.73) MAPTKMT2AALDH1A1MEN1KDM4E
Indole-3-Acetic Acid SCHEMBL11125791 0.80 MEN1 (0.73) MAPTKMT2AALDH1A1MEN1KDM4E
Indole-3-Acetic Acid SCHEMBL468233 0.80 MEN1 (0.73) MAPTKMT2AALDH1A1MEN1KDM4E
Indole-3-Acetic Acid SCHEMBL31152574 0.80 MEN1 (0.73) MAPTKMT2AALDH1A1MEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209571-A1 Phenanthrene derivatives as MPGES-1 inhibitors CELLUMEN INC. 2009-08-20 US disclosed
EP-2024371-A1 PHENANTHRENE DERIVATIVES AS MPGES-1 INHIBITORS Merck Frosst Canada Ltd. (CA) 2009-02-18 EP disclosed
WO-2007134434-A1 PHENANTHRENE DERIVATIVES AS MPGES-1 INHIBITORS MERCK FROSST CANADA LTD. (CA) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209571-A1 Phenanthrene derivatives as MPGES-1 inhibitors PTGES, PTGS1, PTGES2 MAPT 3703/4885KMT2A 2400/4885ALDH1A1 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.